Fig. 1: Expression of HERV proteins in ovarian carcinoma. | Communications Biology

Fig. 1: Expression of HERV proteins in ovarian carcinoma.

From: Enhanced antitumoral activity of TLR7 agonists via activation of human endogenous retroviruses by HDAC inhibitors

Fig. 1

a ERVWE1 (syncytin 1), ERVFRD-1 (syncytin 2), HERV-V1/V2, ERVMER34-1 and ERV3-1 are expressed in the SKOV3WT ovarian carcinoma cell line. Of note, in the carboplatin-refractory SKOV3CP subline, these envelope proteins are remarkably overexpressed, establishing a correlation between HERV expression and high chemotherapy resistance. Isolated ascites cells deriving from heavily carboplatin-treated ovarian carcinoma are highly positive for HERV-V1/V2 envelope proteins. b In tissue paraffin sections from ovarian carcinoma of epithelial origin, HERV-V1/V2 expression is mainly confined to the tumour area. It is low in the tumour stromal tissues and almost absent in regular ovarian tissues (IHC analysis, magnification ×20). Results are representative of n = 10 analysed specimens.

Back to article page